Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases
Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B<sub>12</sub>. In a pilot randomized controlled trial of the Mediterranean diet (...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/11/5/1020 |
id |
doaj-27085d3ee10e448cb704e7f45f473928 |
---|---|
record_format |
Article |
spelling |
doaj-27085d3ee10e448cb704e7f45f4739282020-11-24T20:46:44ZengMDPI AGNutrients2072-66432019-05-01115102010.3390/nu11051020nu11051020Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic DiseasesAntonio Mastroianni0Chiara Maura Ciniselli1Rossella Panella2Alessandra Macciotta3Adalberto Cavalleri4Elisabetta Venturelli5Francesca Taverna6Arabella Mazzocchi7Eleonora Bruno8Paola Muti9Franco Berrino10Paolo Verderio11Daniele Morelli12Patrizia Pasanisi13Laboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyLaboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyImmunohematology and Transfusion Medicine Service-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyChair Cancer Experimental Therapeutics, Department of Oncology Faculty of Health Science, McMaster University, Hamilton, ON L8V 1C3, CanadaEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyBioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyLaboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyEpidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, ItalyMetformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B<sub>12</sub>. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, we tested the effect of MET on serum levels of B<sub>12</sub>, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years. Results of the study indicate a significant overall reduction in both serum total B<sub>12</sub> and holo-TC-II levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of the 84 placebo-treated subjects had B<sub>12</sub> below the normal threshold (<221 pmol/L) at the end of the study. Considering jointly all B<sub>12</sub>, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and 3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study, without reporting clinical signs. Although our results do not affect whether women remain in the trial, B<sub>12</sub> monitoring for MET-treated individuals should be implemented.https://www.mdpi.com/2072-6643/11/5/1020metforminvitamin B<sub>12</sub>holotranscobalamin IImethylmalonic acid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonio Mastroianni Chiara Maura Ciniselli Rossella Panella Alessandra Macciotta Adalberto Cavalleri Elisabetta Venturelli Francesca Taverna Arabella Mazzocchi Eleonora Bruno Paola Muti Franco Berrino Paolo Verderio Daniele Morelli Patrizia Pasanisi |
spellingShingle |
Antonio Mastroianni Chiara Maura Ciniselli Rossella Panella Alessandra Macciotta Adalberto Cavalleri Elisabetta Venturelli Francesca Taverna Arabella Mazzocchi Eleonora Bruno Paola Muti Franco Berrino Paolo Verderio Daniele Morelli Patrizia Pasanisi Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases Nutrients metformin vitamin B<sub>12</sub> holotranscobalamin II methylmalonic acid |
author_facet |
Antonio Mastroianni Chiara Maura Ciniselli Rossella Panella Alessandra Macciotta Adalberto Cavalleri Elisabetta Venturelli Francesca Taverna Arabella Mazzocchi Eleonora Bruno Paola Muti Franco Berrino Paolo Verderio Daniele Morelli Patrizia Pasanisi |
author_sort |
Antonio Mastroianni |
title |
Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases |
title_short |
Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases |
title_full |
Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases |
title_fullStr |
Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases |
title_full_unstemmed |
Monitoring Vitamin B<sub>12</sub> in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases |
title_sort |
monitoring vitamin b<sub>12</sub> in women treated with metformin for primary prevention of breast cancer and age-related chronic diseases |
publisher |
MDPI AG |
series |
Nutrients |
issn |
2072-6643 |
publishDate |
2019-05-01 |
description |
Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B<sub>12</sub>. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, we tested the effect of MET on serum levels of B<sub>12</sub>, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years. Results of the study indicate a significant overall reduction in both serum total B<sub>12</sub> and holo-TC-II levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of the 84 placebo-treated subjects had B<sub>12</sub> below the normal threshold (<221 pmol/L) at the end of the study. Considering jointly all B<sub>12</sub>, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and 3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study, without reporting clinical signs. Although our results do not affect whether women remain in the trial, B<sub>12</sub> monitoring for MET-treated individuals should be implemented. |
topic |
metformin vitamin B<sub>12</sub> holotranscobalamin II methylmalonic acid |
url |
https://www.mdpi.com/2072-6643/11/5/1020 |
work_keys_str_mv |
AT antoniomastroianni monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT chiaramauraciniselli monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT rossellapanella monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT alessandramacciotta monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT adalbertocavalleri monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT elisabettaventurelli monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT francescataverna monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT arabellamazzocchi monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT eleonorabruno monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT paolamuti monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT francoberrino monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT paoloverderio monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT danielemorelli monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases AT patriziapasanisi monitoringvitaminbsub12subinwomentreatedwithmetforminforprimarypreventionofbreastcancerandagerelatedchronicdiseases |
_version_ |
1716811697564418048 |